RE:RE:RE:RE:RE:Immunity bio doing wellfredgoodwinson wrote: Immunity Bio`s results are impressive but treatment looks to involve 2 x series of 6 instillations (including BCG) plus 3-year maintenance? In contrast and where TLT could really shine is through the reduction of an overwhelming and increasing workload in Public Health and beyond.
Imagine only 2 x outpatient treatments (six months apart) for refractory NMIBC? - or (thanks for the heads up Dawg) those given a diagnosis of later stage lung cancer booked in for a jab and an x-ray (with or without adjuvants)?
It is injectable Rutherrin (we are told here currently under development) that will take TLT to the next level with such treatments - the sooner it arrives the better for all.
From a late 2021 article in the MedicalNewsToday newsletter....noting that in select cases (early stage, smaller lesions), PDT can be "curative". My hope is X-ray PDT with Rutherrin could further expand treatment opportunities as either a stand-alone or as an adjunct...& minimizing the side effect of light sensitivity, which has always been one of the primary drawbacks of earlier generations of photosensitizers.
NSCLC is the most common type of lung cancer, making up about 80–85%Trusted Source of all cases.
A range of treatments is available for NSCLC, with the best option varying depending on the stage of the cancer, its rate of progression, and the goal of treatment.
PDT may have a role to play in treating NSCLC in some specific cases, such as in the very early stages of the disease. Research from 2021Trusted Source notes that people with only small lesions under 1 centimeter long may be good candidates for PDT. In these cases, where PDT can effectively eliminate the cancer, this treatment should cure the disease.
Once NSCLC has progressed, doctors may still consider adding PDT as a part of therapy.
One of the major benefits of PDT is that it does not compromise future treatments, making it a possible adjunct therapy in necessary cases. People who undergo PDT can still have other forms of cancer therapy at a later stage.
PDT may also help treat airway blockages resulting from advanced, inoperable lung cancer. Research from 2019 notes that in a prospective trial investigating the effects of adding PDT to radiation therapy, the combined treatment was much more effective than radiation therapy alone in opening the airways.
Only 10% of people in the radiation therapy group experienced a complete opening of their airways in comparison with 70% of those in the combined treatment group.
PDT may also have a role in palliative care for those with advanced cancers. Research from 2021Trusted Source notes that PDT is an alternative to chemotherapy or radiation therapy for palliative care. The authors explain that as a stand-alone treatment, it achieved an overall 87% response rate and improved quality of life.